JP5513741B2 - プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 - Google Patents

プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 Download PDF

Info

Publication number
JP5513741B2
JP5513741B2 JP2008513829A JP2008513829A JP5513741B2 JP 5513741 B2 JP5513741 B2 JP 5513741B2 JP 2008513829 A JP2008513829 A JP 2008513829A JP 2008513829 A JP2008513829 A JP 2008513829A JP 5513741 B2 JP5513741 B2 JP 5513741B2
Authority
JP
Japan
Prior art keywords
procaspase
pac
cells
caspase
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008513829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545718A5 (enExample
JP2008545718A (ja
Inventor
ポール， ジェイ． ハーゲンロザー，
カーソン， エス． パット，
グレイス， ダブリュー． チェン，
ジェニファー， エム． ペアソン，
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
Publication of JP2008545718A publication Critical patent/JP2008545718A/ja
Publication of JP2008545718A5 publication Critical patent/JP2008545718A5/ja
Application granted granted Critical
Publication of JP5513741B2 publication Critical patent/JP5513741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2008513829A 2005-05-26 2006-05-26 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 Active JP5513741B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68480705P 2005-05-26 2005-05-26
US60/684,807 2005-05-26
US74387806P 2006-03-28 2006-03-28
US60/743,878 2006-03-28
US11/420,425 2006-05-25
US11/420,425 US20070049602A1 (en) 2005-05-26 2006-05-25 Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
PCT/US2006/020910 WO2006128173A2 (en) 2005-05-26 2006-05-26 Selective apoptotic induction in cancer cells including activation of procaspase-3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012251584A Division JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Publications (3)

Publication Number Publication Date
JP2008545718A JP2008545718A (ja) 2008-12-18
JP2008545718A5 JP2008545718A5 (enExample) 2009-07-16
JP5513741B2 true JP5513741B2 (ja) 2014-06-04

Family

ID=37452994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008513829A Active JP5513741B2 (ja) 2005-05-26 2006-05-26 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導
JP2012251584A Active JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012251584A Active JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Country Status (10)

Country Link
US (1) US20070049602A1 (enExample)
EP (3) EP2634581A1 (enExample)
JP (2) JP5513741B2 (enExample)
AU (1) AU2006251978A1 (enExample)
CA (1) CA2610366A1 (enExample)
DK (1) DK1893210T3 (enExample)
ES (1) ES2763156T3 (enExample)
IL (1) IL187603A0 (enExample)
MX (1) MX2007014843A (enExample)
WO (1) WO2006128173A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) * 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
WO2010091382A1 (en) 2009-02-09 2010-08-12 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
WO2010102513A1 (zh) * 2009-03-11 2010-09-16 深圳市湘雅生物医药研究院 高哌嗪乙酰肼类衍生物及其制备方法和用途
CN101805338B (zh) * 2010-04-06 2014-10-15 沈阳药科大学 噁二唑基哌嗪衍生物及其用途
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
EP2819661B1 (en) 2012-03-02 2016-11-09 The Board of Trustees of the University of Illionis Potent anticancer activity via dual compound activation
MX365392B (es) * 2012-03-06 2019-05-31 Univ Illinois Composición de combinación de pac-1 y doxorrubicina.
JP6222608B2 (ja) * 2012-03-06 2017-11-01 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 膠芽腫のためのプロカスパーゼ併用療法
US9249116B2 (en) * 2012-08-03 2016-02-02 The Board Of Trustees Of The University Of Illinois Enzyme-activating compounds and compositions
CN105218399B (zh) 2014-05-30 2018-02-09 中国人民解放军军事医学科学院毒物药物研究所 一种取代乙酰肼类衍生物、其制备方法及用途
WO2016197129A1 (en) 2015-06-05 2016-12-08 The Board Of Trustees Of The University Of Illinois Pac-1 combination therapy
EP3326631B1 (en) * 2015-07-23 2021-07-14 Zhimin Wang Compound pac-1 or salt thereof, and pharmaceutical composition comprising same
WO2017015784A1 (zh) * 2015-07-24 2017-02-02 深圳市湘雅生物医药研究院 奥比特嗪-富马酸盐、水合物、晶型及其制备方法
CN105085421B (zh) * 2015-07-24 2017-12-26 深圳市湘雅生物医药研究院 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
AU2018368453B2 (en) * 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
KR20210084442A (ko) 2018-10-05 2021-07-07 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 포도막 흑색종 치료를 위한 병용 요법
WO2025129066A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of California Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4068666B2 (ja) * 1997-05-22 2008-03-26 ザ バーナム インスティチュート カスパーゼ活性のアポトーシスインヒビター（ｉａｐ）タンパク質調節を変える薬剤についてのスクリーニングアッセイ
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
AU5205499A (en) 1998-07-27 2000-02-21 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
KR100439425B1 (ko) * 2001-03-22 2004-07-05 (주)바이오케어 잔토리졸을 포함하는 조성물 및 그 용도
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
CA2508690A1 (en) * 2002-12-10 2004-06-24 Ottawa Health Research Institute Modulation of stem cell differentiation by modulation of caspase-3 activity
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3

Also Published As

Publication number Publication date
MX2007014843A (es) 2008-02-14
AU2006251978A1 (en) 2006-11-30
EP2634581A1 (en) 2013-09-04
EP1893210A4 (en) 2010-09-01
JP5907852B2 (ja) 2016-04-26
WO2006128173A3 (en) 2007-05-24
WO2006128173A2 (en) 2006-11-30
DK1893210T3 (da) 2020-01-13
EP2659884A3 (en) 2014-10-01
CA2610366A1 (en) 2006-11-30
EP1893210B1 (en) 2019-10-02
EP1893210A2 (en) 2008-03-05
US20070049602A1 (en) 2007-03-01
ES2763156T3 (es) 2020-05-27
JP2008545718A (ja) 2008-12-18
IL187603A0 (en) 2008-03-20
JP2013100285A (ja) 2013-05-23
EP2659884A2 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
JP5907852B2 (ja) プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導
US11612598B2 (en) Compounds and methods for the treatment of cancer
Yuan et al. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Agarwal et al. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells
Smith et al. Synthetic analogs of green tea polyphenols as proteasome inhibitors
Hamdoun et al. Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity
US11584718B2 (en) Activators of the unfolded protein response
JP2015025021A (ja) 個別化された抗癌薬としてのプロカスパーゼ活性化化合物の設計、合成および評価
Hockenbery et al. Mitochondria and apoptosis: new therapeutic targets
Wang et al. Targeting procaspase‐3 with WF‐208, a novel PAC‐1 derivative, causes selective cancer cell apoptosis
Romagnoli et al. Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents
CN101184491A (zh) 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20090163577A1 (en) METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS
Wang et al. Novel thiohydantoin analogues bearing the 1-hydroxyl-2, 2, 2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer
KR101400505B1 (ko) Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
CN116768919B (zh) 取代氨基苯基呋喃并吡啶化合物及其制备方法、药物组合物和应用
US20250114313A1 (en) Oligo-benzamide analogs and their use in cancer treatment
Song et al. Discovery of SA-8 as a Potent SHP2-AUTAC Degrader in Cancer Therapy
JP2012102087A (ja) タンパク質リシンメチル化酵素Ｓｅｔ７／９の阻害物質を含有する疾患の予防・治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130515

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140328

R150 Certificate of patent or registration of utility model

Ref document number: 5513741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250